Epithelial Ovarian Cancer Clinical Trials

247 clinical trials for Epithelial Ovarian Cancer across international registries, including 55 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. — RECRUITING · PHASE2
• Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer — RECRUITING
• Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer — RECRUITING · NA
• Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE3
• A Study of Isoquercetin in People With Ovarian Cancer — RECRUITING · PHASE2
• Centralization and Oncologic Outcomes in Ovarian Cancer — RECRUITING
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer — RECRUITING · PHASE3
• [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications — RECRUITING · PHASE2
• A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) — RECRUITING · PHASE3
• A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) — RECRUITING · NA
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications — RECRUITING · PHASE1
• CT-95 in Advanced Cancers Associated With Mesothelin Expression — RECRUITING · PHASE1
• Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 — RECRUITING · PHASE1
• Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells — RECRUITING · PHASE1
• Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer — RECRUITING · PHASE1
• Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer — RECRUITING · PHASE2
• A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer — RECRUITING · PHASE1
• Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) — RECRUITING · NA
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
• Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) — RECRUITING · PHASE1
• Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT — RECRUITING · PHASE1
• Determining Prognostic Immune Markers in Patients With Ovarian Cancer — RECRUITING
• A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers — RECRUITING · PHASE1
• A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE1
• CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. — RECRUITING · PHASE2
• Study of AVZO-021 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer — RECRUITING · NA
• NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer — RECRUITING · PHASE1
• Platino-resistance in Ovarian Cancer — RECRUITING · NA
• The Immune Landscape of Epithelial Ovarian Cancer — RECRUITING
• A RANDOMISED, OPEN-LABEL, PHASE III STUDY OF AZD5335 VERSUS MIRVETUXIMAB SORAVTANSINE IN FR¿-HIGH AND AZD5335 VERSUS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN FR¿-LOW EXPRESSING HIGH-GRADE PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS (TREVI-OC-01) — RECRUITING · PHASE3
• WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC — RECRUITING · PHASE2
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors — RECRUITING · PHASE1
• Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) — RECRUITING
• A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers — RECRUITING · PHASE1
• Cukurova Score Validation Study — RECRUITING
• Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery — RECRUITING · NA
• Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC — RECRUITING · PHASE2
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
• A PHASE 2 OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN (STRO-002) IN WOMEN WITH RELAPSED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS) EXPRESSING FOLATE RECEPTOR ALPHA (FOLR1) — RECRUITING · PHASE2
• A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA) — RECRUITING · PHASE3
• 68GA-FAPI PET/CT IN THE STAGING OF HIGH GRADE EPITHELIAL OVARIAN CANCERS: A PILOT STUDY — RECRUITING
• RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE AS MAINTENANCE THERAPY FOR PATIENTS WITH FRA-HIGH RECURRENT PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERS WHO HAVE NOT PROGRESSED AFTER SECOND-LINE PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB (GLORIOSA) — RECRUITING · PHASE3
• MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE2
• RE-VOLVE: A PHASE II CLINICAL TRIAL IN WOMEN WITH OVARIAN CANCER PROGRESSING POST-PARP INHIBITOR WITH TREATMENT ADAPTED TO REAL-TIME ASSESSMENT OF EVOLVING GENOMIC RESISTANCE — RECRUITING · PHASE2
• PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI — RECRUITING · PHASE1
• A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS — RECRUITING · PHASE2
• AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUBJECTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH NIRAPARIB (3000-04-003) — RECRUITING
• A MULTICENTER, OPEN-LABEL, PARALLEL, PHASE 2A STUDY OF PLX2853 MONOTHERAPY IN ADVANCED GYNECOLOGICAL MALIGNANCIES WITH A KNOWN ARID1A MUTATION AND PHASE 1B/2A STUDY OF PLX2853/CARBOPLATIN COMBINATION THERAPY IN PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER — RECRUITING · PHASE2
• MIRASOL: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE VS. INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN ADVANCED HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION — RECRUITING · PHASE3

Refine this search